title: [Expression and significance of survivin in colon cancer].
abstract: OBJECTIVE
  Survivin is a newly identified apoptosis inhibitor. Studies indicated that Survivin over-expressed in malignant tumors. This study was designed to evaluate the expression of Survivin in colon cancer,and the correlation of its expression to clinical characteristics and prognosis of patients with colon cancer.
  
  
  METHODS
  Expression of Survivin protein was investigated by immunohistochemistry in 12 cases of normal colon tissues,and 79 cases of colon cancer tissues without the history of radiotherapy or chemotherapy.
  
  
  RESULTS
  Expression of Survivin was detected in 78.5%(62/79) of colon cancer tissues,higher than that in tumor nests adjacent tissues, which was 32.9% (26/79). In contrast, normal colon tissues did not express Survivin. There was no relationship between the expression of Survivin and age, sex, blood type, serum CEA level, lymph node metastasis, histological grade, infiltration degree, and Dukes' stage(P >0.05). When 25% was used as the cut-off point between high and low expression of Survivin, 3-year overall survival rate of low expression group (63.56%) was much higher than that of high expression group (39.96%) (P=0.04). Cox proportional hazards model analysis showed that Dukes' stage, and high expression of Survivin were the only 2 prognosis factors influenced the survival times (Wald values were 24.225, and 5.504, respectively, P values were 0.000, and 0.019, respectively).
  
  
  CONCLUSIONS
  There is a high expression level of Survivin in colon cancer, it may play an important role in tumorgenesis and development of colon cancer. Over-expression of Survivin was related with poor prognosis, it may be a potential prognostic index.
authors.affiliation: Department of Oncology, The Second Affiliated Hospital, Sun Yet-sen University, Guangzhou, Guangdong, 510120, P.R.China.
authors.forename: Zhi-Min
authors.initials: ZM
authors.lastname: Jiang
authors.forename: He-Rui
authors.initials: HR
authors.lastname: Yao
authors.forename: Jun
authors.initials: J
authors.lastname: Zhan
authors.forename: De-Rong
authors.initials: DR
authors.lastname: Xie
authors.forename: Hai-Gang
authors.initials: HG
authors.lastname: Li
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003106:Colon / Q000378:metabolism; D003110:Colonic Neoplasms / Q000378:metabolism* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D008297:Male; D008869:Microtubule-Associated Proteins / Q000378:metabolism*; D008875:Middle Aged; D009363:Neoplasm Proteins; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models; D015996:Survival Rate; D000077022:Survivin
chemical_list: C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D000077022:Survivin